In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.

Efforts to innovate in the fight against influenza include universal influenza vaccines — none successful so far. Merck is aiming for universality with a drug, not a vaccine, via the $9.2 billion ...

An antiviral pill has shown to be effective in treating COVID-19, according to Phase 2 trial results released late last week. Should those promising results continue in large-scale Phase 3 trials, the ...

Merck plans to acquire Cidara Therapeutics Inc. in a deal worth $9.2 billion. As part of a deal announced Nov. 14, the Rahway-based drugmaker will gain access to the San Diego-headquartered biotech’s ...

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...